Kim Tae-Hun, Kang Jung Won, Jeon Sae-Rom, Ang Lin, Lee Hye Won, Lee Myeong Soo
Korean Medicine Clinical Trial Center, Korean Medicine Hospital, Kyung Hee University, Seoul, South Korea.
Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, South Korea.
Front Med (Lausanne). 2022 May 9;9:884573. doi: 10.3389/fmed.2022.884573. eCollection 2022.
Traditional, Complementary and Integrative Medicine (TCIM) has been reported to use for symptom management of coronavirus disease 2019 (COVID-19). The objective of this review was to identify the overall usage prevalence of TCIM interventions for COVID-19.
Surveys on the general population and observational studies on the COVID-19 patient chart review were located in the search of PubMed, EMBASE and Cochrane Central Register of Controlled Trials databases in September 2021. Observational studies, such as cross-sectional studies, surveys, cohort studies and hospital-based patient case reviews, published in any language, reporting the usage of TCIM in the patients with COVID-19 or the general population during the COVID-19 pandemic were included in this review. Data screening and extraction were performed independently by two reviewers. The reporting quality of the included studies was assessed with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement. To conduct a meta-analysis of the usage prevalence of various TCIM interventions, the effect size of the proportion for each intervention was calculated with the inverse variance method. The main outcome was usage prevalence of TCIM interventions among patients with COVID-19 or the general population during the COVID-19 pandemic.
A total of 62 studies were included in this review. The overall TCIM usage prevalence was estimated to be 0.64 (95% CI 0.54-0.73). The overall prevalence did not differ between the population-based survey (0.65, 95% CI 0.48-0.81) and the hospital-based patient case review (0.63, 95% CI 0.52-0.73). Statistical heterogeneity and comparatively low quality in reporting were observed, which should be cautiously considered when interpreting the results.
Various TCIM interventions were reported to be used with comparatively high frequency. Future international collaborative research might overcome the main limitation of this study, i.e., the heterogeneity of the included data.
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=278452, identifier: CRD42021278452.
据报道，传统、补充和整合医学（TCIM）被用于2019冠状病毒病（COVID-19）的症状管理。本综述的目的是确定TCIM干预措施在COVID-19中的总体使用 prevalence。
2021年9月在PubMed、EMBASE和Cochrane对照试验中央注册库数据库中检索关于普通人群的调查以及对COVID-19患者病历审查的观察性研究。纳入本综述的观察性研究，如横断面研究、调查、队列研究和基于医院的患者病例审查，以任何语言发表，报告COVID-19大流行期间COVID-19患者或普通人群中TCIM的使用情况。由两名 reviewers 独立进行数据筛选和提取。使用流行病学观察性研究报告强化（STROBE）声明评估纳入研究的报告质量。为了对各种TCIM干预措施的使用 prevalence 进行荟萃分析，使用逆方差法计算每种干预措施比例的效应大小。主要结果是COVID-19大流行期间COVID-19患者或普通人群中TCIM干预措施的使用 prevalence。
本综述共纳入62项研究。TCIM的总体使用 prevalence 估计为0.64（95%CI 0.54-0.73）。基于人群的调查（0.65，95%CI 0.48-0.81）和基于医院的患者病例审查（0.63，95%CI 0.52-0.73）之间的总体 prevalence 没有差异。观察到统计异质性和报告质量相对较低，在解释结果时应谨慎考虑。
据报道，各种TCIM干预措施的使用频率相对较高。未来的国际合作研究可能会克服本研究的主要局限性，即纳入数据的异质性。
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=278452，标识符：CRD42021278452。
